within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AB03_Fluoxetine;

model Fluoxetine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.72,
    Cl = 3.222222222222222e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600,
    Vdp = 0.012,
    k12 = 1.6666666666666667e-06,
    k21 = 1.6666666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fluoxetine</td></tr><tr><td>ATC code:</td><td>N06AB03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>25</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It is an approved medication widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (both sexes), following a single oral dose.</p><h4>References</h4><ol><li><p>Deeks, ED, &amp; Keating, GM (2008). Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. <i>Drugs</i> 68(8) 1115–1137. DOI:<a href=\"https://doi.org/10.2165/00003495-200868080-00008\">10.2165/00003495-200868080-00008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18484802/\">https://pubmed.ncbi.nlm.nih.gov/18484802</a></p></li><li><p>Graff, DW, et al., &amp; Patterson, JH (2001). Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. <i>Journal of clinical pharmacology</i> 41(1) 97–106. DOI:<a href=\"https://doi.org/10.1177/00912700122009746\">10.1177/00912700122009746</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11225566/\">https://pubmed.ncbi.nlm.nih.gov/11225566</a></p></li><li><p>Ozdemir, V, et al., &amp; Naranjo, CA (1996). Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?. <i>Clinical pharmacokinetics</i> 31(5) 372–385. DOI:<a href=\"https://doi.org/10.2165/00003088-199631050-00004\">10.2165/00003088-199631050-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9118585/\">https://pubmed.ncbi.nlm.nih.gov/9118585</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AB03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fluoxetine;
